Combined anti-liver cancer application of everolimus and cucurbitacine I

Through the combined use of everolimus and cucurbitol I, combined with immune checkpoint inhibitors, targeting the IMPDH2/mTOR/STAT3 signaling pathway, the problem of poor chemotherapy and great toxicity of liver cancer is solved, and the efficacy of liver cancer treatment is significantly improved. And reduces the side effects of the drug.

CN119015293APending Publication Date: 2024-11-26TIANJIN TUMOR HOSPITAL
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411154135.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-21
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The chemotherapy treatment effect of liver cancer is not ideal, the existing targeted treatment methods are problematic that are highly toxic and difficult for patients to bear, and there is a lack of effective treatment methods.

Method used

Using a combination of everolimus and cucurbitol I, combined with immune checkpoint inhibitors such as PD-L1 or PD-1 antibodies, significantly inhibits the growth of liver cancer cells by targeting the IMPDH2/mTOR/STAT3 signaling pathway.

Benefits of technology

It significantly improves the efficacy of liver cancer treatment, reduces the toxic side effects of everolimus, provides new clinical application prospects, and provides new targets and methods for liver cancer treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015293A_ABST
    Figure CN119015293A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of tumor treatment, and particularly discloses a novel method for resisting liver cancer by combining everolimus and cucurbitacine I and application. The novel anti-tumor treatment method disclosed by the invention shows a good clinical application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of anti-tumor treatment, and in particular to the use of everolimus and cucurbitacin I in combination in the preparation of an anti-liver cancer drug. Background Art

[0002] Liver cancer refers to malignant tumors that occur in the liver or start from the liver. Primary liver cancer is one of the most common malignant tumors and causes of death from tumors in my country, and it seriously threatens people's life and health. There are many treatment options for liver cancer, including surgery, radiotherapy, radiofrequency ablation, venous embolization, and drug therapy. However, the effect of chemotherapy for liver cancer is not ideal, and there is a great demand for targeted therapy.

[0003] Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) is a rate-limiting enzyme that catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthine 5'-phosphate (XMP), converting intracellular NAD+ into NADH. IMPDH2 is involved in maintaining the cellular guanine deoxy and ribonucleotide pools required for DNA and RNA synthesis. IMPDH2 is upregulated in a variety of malignant tumors and promotes the occurrence and development of colorectal cancer by activating the PI3K / AKT / mTOR and PI3K / AKT / FOXO1 signaling pathways. The expression and significance of IMPDH2 in liver cancer are still unclear.

[0004] Everolimus directly and continuously acts on the mTOR target, effectively inhibiting tumor cell growth and proliferation, nutrient metabolism, and the generation and release of angiogenic factors. Approved indications include gastrointestinal or pulmonary neuroendocrine tumors, HER2-negative advanced breast cancer, etc. The use of everolimus in liver transplant patients with liver cancer has achieved a good prognosis, but the effect of everolimus alone in the treatment of liver cancer is not good. In addition, during clinical use, although everolimus has significant anti-tumor efficacy, it is too toxic for patients to bear, which is a problem for the widespread use of clinical first-line drugs.

[0005] Cucurbitacin I, a natural cell-permeable triterpenoid isolated from the Cucurbitaceae family, is a novel JAK2 / STAT3 selective inhibitor. The effects of cucurbitacin I on the STAT3 signaling pathway include inhibiting STAT3 phosphorylation and inhibiting STAT3 signaling from transmitting proliferation. Currently, cucurbitacin I has been used in the adjuvant treatment of primary liver cancer (approved for marketing by the China Food and Drug Administration, CYZB2101238), with good safety.

[0006] PD-1 / PD-L1 immunotherapy aims to make full use of the body's own immune system to resist and fight cancer. Blocking the PD-1 / PD-L1 signaling pathway is a new anti-cancer method that causes cancer cell death. It is widely used clinically for lung cancer, gastrointestinal tumors, breast cancer, urinary system tumors, skin cancer, lymphoma, etc.

[0007] However, effective treatments are still needed for liver cancer. Summary of the invention

[0008] The present invention aims to improve the anti-liver cancer efficacy by combining everolimus and cucurbitacin I with immune checkpoint inhibitors such as PD-L1 or PD-1 antibodies in order to address the deficiencies in the field of liver cancer treatment.

[0009] The present invention proposes that IMPDH2 is a new target for tumor treatment, especially liver cancer treatment. IMPDH2 is highly expressed in a variety of tumor tissues, including liver cancer tissues, etc. The inventors of the present invention have found that compared with the single-drug control, the combined use of everolimus and cucurbitacin I has a significant synergistic effect in inhibiting the growth of liver cancer.

[0010] In one aspect, the present invention provides the use of cucurbitacin I in preparing a synergist for everolimus in treating liver cancer.

[0011] In another aspect, the present invention provides a method for improving the therapeutic effect of everolimus in treating liver cancer, comprising administering cucurbitacin I.

[0012] In some specific embodiments, the molar ratio of everolimus to cucurbitacin I is 1:0.1-10, preferably 1:0.2-5, and more preferably 1:0.5-4.

[0013] In another aspect, the present invention provides use of a pharmaceutical composition in preparing a medicament for treating liver cancer, wherein the pharmaceutical composition comprises everolimus and cucurbitacin I.

[0014] In another aspect, the present invention provides a method for treating liver cancer, comprising administering a pharmaceutical composition comprising everolimus and cucurbitacin I.

[0015] In some specific embodiments, in the pharmaceutical composition, the molar ratio of everolimus to cucurbitacin I is 1:0.1-10, preferably 1:0.2-5, and more preferably 1:0.5-4.

[0016] In some embodiments, the synergist or the pharmaceutical composition further comprises an immune checkpoint inhibitor, preferably the immune checkpoint inhibitor comprises a PD-1 antibody and / or a PD-L1 antibody. In some embodiments, the PD-1 antibody is nivolumab and / or pembrolizumab. In some embodiments, the PD-L1 antibody is atezolizumab and / or sintilimab.

[0017] In another aspect, the present invention provides use of an mTOR inhibitor and a STAT3 inhibitor in preparing a medicament for treating liver cancer.

[0018] In another aspect, the present invention provides a method for treating liver cancer, comprising administering an mTOR inhibitor and a STAT3 inhibitor.

[0019] In some embodiments, the mTOR inhibitor and / or the STAT3 inhibitor further inhibits the activity of IMPDH2.

[0020] In some specific embodiments, the mTOR inhibitor and the STAT3 inhibitor are each independently selected from one or more of a small molecule compound, an antibody, an RNAi molecule, and an antisense nucleic acid.

[0021] In some embodiments, the mTOR inhibitor is selected from everolimus.

[0022] In some embodiments, the STAT3 inhibitor is selected from cucurbitacin I.

[0023] In some embodiments, the antibody is a monoclonal antibody or a polyclonal antibody. In some embodiments, the antibody is a monospecific antibody or a multispecific antibody. In some embodiments, the antibody is a chimeric antibody, a humanized antibody or a fully human antibody.

[0024] In some embodiments, the RNAi molecule is a small interfering RNA (siRNA), a short hairpin RNA (shRNA), or a micro RNA (miRNA).

[0025] In some embodiments, the RNAi molecule is 18-100 bases in length.

[0026] In some embodiments, the RNAi molecule is modified to enhance its stability.

[0027] In some specific embodiments, the RNAi molecule comprises a nucleotide sequence of any one of SEQ ID NOs: 1-3, or a nucleotide sequence having 80%, 85%, 90%, 95%, 96%, 97%, 98% or more sequence identity with any one of SEQ ID NOs: 1-3.

[0028] Advantageous Effects of the Invention

[0029] The present invention establishes a new anti-tumor combined treatment method for the first time and uses it in the treatment of liver cancer. The results show that the present invention combines everolimus and cucurbitacin I for the first time, showing a good effect of inhibiting the growth of liver cancer. Furthermore, when the combination of everolimus / cucurbitacin I is used in combination with immune checkpoint inhibitors such as PD-1 or PD-L1 antibodies, the inhibitory effect on tumor cell growth is significant, showing a further synergistic effect, providing a new method for the clinical treatment of tumors.

[0030] Based on the IMPDH2 target, the advantages of the combined use of everolimus and cucurbitacin I in the present invention are as follows:

[0031] (1) IMPDH2 is highly expressed in cancer patient tissues, especially in liver cancer tissues. When the IMPDH2 gene is silenced, the growth of liver cancer cells is significantly inhibited, suggesting that IMPDH2 is an ideal target for tumor therapy;

[0032] (2) The present invention found that the complex formed by IMPDH2 / mTOR / STAT3 in liver cancer cells is the basis for IMPDH2 to function. Destroying the integrity of the complex formed by IMPDH2 / mTOR / STAT3 is the pharmacological basis for the combined use of everolimus / cucurbitacin I;

[0033] (3) Everolimus has shown good anti-tumor efficacy in clinical practice, but its toxic side effects make it difficult for patients to tolerate. After reducing the dosage of everolimus, its combination with cucurbitacin I can significantly enhance the efficacy and show good clinical application prospects;

[0034] (4) After clinical liver cancer patients were treated with anti-PD-1, the expression of IMPDH2 in liver cancer tissue was significantly suppressed. The present invention combines PD-L1 or PD-1 antibody inhibitors with the new combination of everolimus / cucurbitacin I to achieve an ideal anti-tumor effect, showing good clinical application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0035] Figure 1 The combined analysis result graph shows that the expression of IMPDH2 in liver cancer tissues of liver cancer patients after anti-PD-1 antibody treatment in the GEO database was significantly inhibited.

[0036] Figure 2 The figure shows the result that IMPDH2 is highly expressed in liver cancer tumor tissues.

[0037] Figure 3 The figure shows the result that the proliferation and migration of liver cancer cells were inhibited after RNA interference with IMPDH2.

[0038] Figure 4 The figure shows the result that the subcutaneous tumor growth of liver cancer cells in nude mice was significantly inhibited after RNA interference with IMPDH2.

[0039] Figure 5 The figure shows the result of using Co-IP and GST-pull down methods to detect the binding of IMPDH2 and mTOR / STAT3 to form a three-component complex.

[0040] Figure 6 The protein structure diagram of the physical binding of IMPDH2 with mTOR or STAT3 is shown using bioinformatics methods.

[0041] Figure 7 The protein structure diagram of the physical binding of IMPDH2 with the mTOR inhibitor everolimus or the STAT3 inhibitor cucurbitacin I is shown using a bioinformatics method. In addition, the result diagram of the physical binding ability of IMPDH2 with mTOR or STAT3 is shown using an in vitro binding force detection method.

[0042] Figure 8 The results of the clone formation assay for the inhibition of liver cancer proliferation by the new combination of everolimus / cucurbitacin I are shown.

[0043] Fig. 9 The results of using the nude mouse subcutaneous tumor formation method to detect the inhibition of liver cancer growth by the new combination of everolimus / cucurbitacin I are shown.

[0044] Fig.10 The results of using the subcutaneous tumor formation method in immunocompetent C57 mice to detect the inhibition of liver cancer growth by the new combination of everolimus / cucurbitacin I combined with PD-L1 or PD-1 antibody inhibitors are shown. DETAILED DESCRIPTION

[0045] The present invention is further described below by means of specific embodiments. Unless otherwise specified, the academic terms used herein have the same meanings as those generally understood by those of ordinary skill in the art.

[0046] Inhibitors

[0047] The term "mTOR inhibitor" used herein refers to a substance targeting mammalian target of rapamycin (mTOR), such as an antibody, a polypeptide, a small molecule compound, an RNAi molecule or an antisense nucleic acid, which can reduce, block, inhibit, eliminate or interfere with the function of mTOR, and the interaction with IMPDH2. For example, it can reduce, block, inhibit, eliminate or interfere with more than 10%, more than 20%, more than 40%, more than 60%, more than 80%, more than 90% of the biological function of mTOR, or more than 10%, more than 20%, more than 40%, more than 60%, more than 80%, more than 90% of the interaction between mTOR and IMPDH2. The mTOR specific inhibitor herein can play an anti-tumor effect by blocking the formation of the IMPDH2 / mTOR complex. As an mTOR inhibitor, for example, rapamycin (Rapamycin) and its derivatives (Rapalogs), everolimus, etc.

[0048] The term "STAT3 inhibitor" used herein refers to a substance targeting signal transduction and transcription activator 3 (STAT3), such as an antibody, a polypeptide, a small molecule compound, an RNAi molecule or an antisense nucleic acid, which can reduce, block, inhibit, eliminate or interfere with the function of STAT3, and the interaction with IMPDH2. For example, it can reduce, block, inhibit, eliminate or interfere with more than 10%, more than 20%, more than 40%, more than 60%, more than 80%, more than 90% of the biological function of STAT3, or more than 10%, more than 20%, more than 40%, more than 60%, more than 80%, more than 90% of the interaction between STAT3 and IMPDH2. The STAT3 specific inhibitor herein can exert an anti-tumor effect by blocking the formation of the IMPDH2 / STAT3 complex. As a STAT3 inhibitor, for example, cucurbitacin I can be used.

[0049] In some embodiments, the mTOR inhibitor and / or STAT3 inhibitor is an antibody, such as a full-length antibody or an antigen-binding fragment thereof. The term "antigen-binding fragment" as used herein refers to an antibody fragment formed by an antibody fragment containing one or more CDRs but not having a complete antibody structure. Examples of antigen-binding fragments include, but are not limited to, Fab fragments, Fab' fragments, F(ab')2 fragments, Fv fragments, single-chain antibody molecules (scFv), scFv dimers, camelized single-domain antibodies, and nanobodies.

[0050] In some embodiments, the mTOR inhibitor and / or STAT3 inhibitor is a polypeptide.

[0051] In some embodiments, the mTOR inhibitor and / or STAT3 inhibitor is a small molecule compound.

[0052] As used herein, the term "small molecule compound" refers to an organic compound having a molecular weight of less than 3000, 2500, 2000, 1500, 1000 or 500 Daltons, which may be natural or chemically synthesized.

[0053] In some embodiments, the mTOR inhibitor and / or STAT3 inhibitor is an RNAi molecule.

[0054] The term "RNAi molecule" as used herein refers to RNA or its analogs, which have sufficient sequence complementarity with a target RNA to guide RNA interference. In some embodiments, DNA that can be used to generate RNA is also included. RNA interference (RNAi) refers to a sequence-specific or selective process by which a target molecule (e.g., a target gene, protein, or RNA) is downregulated.

[0055] In some embodiments, the RNAi molecule is a small interfering RNA (siRNA), a short hairpin RNA (shRNA), or a micro RNA (miRNA).

[0056] The term "small interfering RNA (siRNA)" as used herein refers to an RNA molecule, preferably a double-stranded molecule, having a length of about 10-50 nucleotides, preferably a length of about 15-25 nucleotides, more preferably a length of about 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides, the strand optionally having an overhanging end comprising, for example, 1, 2 or 3 overhanging nucleotides (or nucleotide analogs), which is capable of directing or mediating the degradation of the RNA.

[0057] The term "short hairpin RNA (shRNA)" as used herein refers to an RNA molecule having a stem-loop structure, which includes a first region and a second region of complementary sequence, the degree of complementarity and the orientation of the regions are sufficient to allow base pairs to appear between the regions, the first region and the second region are connected by the loop region, and the loop is generated by the lack of base pairing between nucleotides (or nucleotide analogs) in the loop region.

[0058] The term "microRNA (microRNA or miRNA)" as used herein is a short, naturally occurring non-coding single-stranded RNA molecule with a length of about 16-26 nucleotides (nt) (e.g., about 16-29nt, 19-22nt, 20-25nt, or 21-23nt), which is usually involved in regulating gene expression in vivo. In eukaryotic cells, miRNA genes are transcribed into "primary products" (pri-miRNA) by DNA transcriptase II, and pri-miRNA is quickly processed into miRNA "precursors" (pre-miRNA) by a ribonuclease III (Drosha), and pre-miRNA is transported from the nucleus to the cytoplasm, and then recognized and sheared into mature miRNA by another ribonuclease III (Dicer). Mature miRNA molecules are complementary to one or more mRNA parts and regulate protein expression. The sequences of known miRNAs can be obtained through public databases, such as the miRBase database (www.mirbase.org), which provides information including miRNA sequence information, functional annotations, and predicted gene targets. In the present disclosure, miRNA also includes RNA molecules with structures and functions similar to natural miRNAs expressed in cells by artificially synthesized plasmids, which can target corresponding mRNAs like natural miRNAs and hinder their translation into proteins. In some embodiments, the length of the RNAi molecule is 18-100 bases. In some embodiments, the RNAi molecule is modified to enhance its stability.

[0059] In some embodiments, the RNAi molecule comprises a nucleotide sequence of SEQ ID NO: 1 (si-IMPDH2_1: AAUGAGAAAGUCAUUGUAGGU), SEQ ID NO: 2: (si-IMPDH2_2: UUUGAGAAAAUCAAUGUCCCU), SEQ ID NO: 3 (si-IMPDH2_3: ACUUGAUCAUAUUGAUCUGG), or a nucleotide sequence having at least 80% (preferably 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or more) sequence identity with any one of SEQ ID NOs: 1-3. In some embodiments, the RNAi molecules of the present disclosure have no reduced or increased IMPDH2 / mTOR and / or IMPDH2 / STAT3 interaction inhibitory activity relative to the RNAi molecules of any one of SEQ ID NOs: 1-3.

[0060] In some embodiments the mTOR inhibitor and / or STAT3 inhibitor is an antisense nucleic acid.

[0061] The term "antisense nucleic acid" as used herein includes nucleotides that are completely complementary to the target sequence and those with one or more nucleotide mismatches, as long as the antisense nucleic acid can specifically hybridize with the target sequence. For example, the antisense nucleic acid herein includes polynucleotides that have at least 70% or more, preferably 80% or more, more preferably 90% or more, and even more preferably 95% or more identity over a length of at least 15 consecutive nucleotides. Due to the formation of a hybrid, transcription of the target gene and / or translation of the target mRNA is reduced or blocked.

[0062] The term "immune checkpoint inhibitor" as used herein refers to a substance that inhibits or blocks the interaction between surface receptors of immune cells (such as T cells) and ligands on the surface of tumor cells, such as antibodies, peptides, small molecule compounds, RNAi molecules, or antisense nucleic acids. "Immune checkpoint molecules" include molecules that enhance immune signals to tumor cells (i.e., "co-stimulatory molecules"), or molecules that reduce immune signals to tumor cells (i.e., "inhibitory immune checkpoint molecules"). In this article, immune checkpoint molecules include PD-1 and PD-L1.

[0063] The ability of immune checkpoint inhibitors to treat cancer depends on the presence of tumor antigen-specific T cells within tumor tissue. This requires that tumor tissue expresses antigens that distinguish itself from its non-transformed counterparts, for example, through novel protein products known as neoantigens. Tumor neoantigen load is closely associated with immunogenicity and sensitivity (e.g., sensitivity to immune checkpoint inhibitor therapy), meaning that tumors with poor immunogenicity should be largely resistant to these drugs. Therapies designed to release tumor antigens that can be taken up by APCs, such as inducing immunogenic cell death (ICD), may promote effective antitumor immunity, especially when further combined with immune checkpoint inhibitors.

[0064] The PD-1 antibody may be, for example, nivolumab and / or pembrolizumab. The PD-L1 antibody may be, for example, atezolizumab and / or sintilimab.

[0065] The term "potentiator" means that compared with the use of a drug for treating liver cancer alone, the combined use of a potency agent can synergistically improve, promote or enhance the efficacy of the drug.

[0066] Pharmaceutical composition

[0067] In some embodiments, the pharmaceutical composition of the present disclosure comprises an mTOR inhibitor (such as everolimus) and a STAT3 inhibitor (such as cucurbitacin I). In some embodiments, the pharmaceutical composition of the present disclosure comprises an mTOR inhibitor and a STAT3 inhibitor, and an immune checkpoint inhibitor (such as a PD-1 antibody and / or a PD-L1 antibody). Specific PD-1 antibodies may be, for example, pembrolizumab and nivolumab. In some embodiments, the pharmaceutical composition of the present disclosure further comprises a pharmaceutically acceptable carrier.

[0068] In the present invention, the molar ratio of mTOR inhibitor (such as everolimus) to STAT3 inhibitor (such as cucurbitacin I) can be 1:0.1-10, preferably 1:0.2-5, 1:0.5-4, 1:0.5-2.5 or 1:0.5-1.5. In some specific embodiments, the above molar ratio can be, for example, 1:0.1, 1:0.2, 1:0.3, 1:0.5, 1:0.7, 1:1, 1:1.2, 1:1.5, 1:1.6, 1:1.7, 1:0.8, 1:2, 1:2.1, 1:2.5, 1:3, 1:3.2, 1:3.5, 1:4, etc.

[0069] In the present invention, the dosage of the mTOR inhibitor (such as everolimus) is 1-20 mg / kg body weight, such as 2.5 mg / kg; the dosage of the STAT3 inhibitor (such as cucurbitacin I) is 1-20 mg / kg body weight, such as 5 mg / kg.

[0070] The term "carrier" as used herein refers to any conventional type of solid, semi-solid or liquid filler, diluent, encapsulation material, formulation auxiliary or excipient. "Pharmaceutically acceptable carrier" refers to a non-toxic "carrier". Pharmaceutically acceptable carriers are non-toxic to the recipient at the dosage and concentration used, and are compatible with the other ingredients of the preparation. Such carriers can be sterilized liquids, such as water and oil, including oils from petroleum, animal, plant or synthetic sources, such as peanut oil, soybean oil, mineral oil, sesame oil, etc. When the pharmaceutical composition is administered intravenously, water is a preferred carrier. Physiological saline solutions and dextrose aqueous solutions and glycerol solutions can also be used as liquid carriers, particularly for injectable solutions. Suitable excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glyceryl monostearate, talc, sodium chloride, anhydrous skim milk, glycerol, propylene glycol, glycol, water, ethanol, etc. If necessary, the composition may also contain a small amount of a wetting agent or emulsifier or a pH buffer. These compositions may take the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained-release formulations, and the like.

[0071] The term "pharmaceutically acceptable" as used herein refers to compounds, materials, compositions and / or dosage forms that are suitable for contact with human and animal tissues without excessive toxicity, irritation, allergic reaction or other problems or complications within the scope of reasonable medical judgment, with a reasonable benefit / risk ratio. In certain embodiments, pharmaceutically acceptable compounds, materials, compositions and / or dosage forms refer to those approved by regulatory agencies (such as the U.S. Food and Drug Administration, the China Food and Drug Administration or the European Medicines Agency) or listed in generally recognized pharmacopoeias (such as the U.S. Pharmacopoeia, the Chinese Pharmacopoeia or the European Pharmacopoeia) for animals (more particularly for humans).

[0072] Drug administration and medical use

[0073] As used herein, the term "liver cancer" is intended to include primary, ie, cancers that originate in the liver. Liver cancers include, for example, hepatocellular carcinoma (HCC) and intrahepatic bile duct carcinoma that originate in liver cells.

[0074] In some embodiments, the liver cancer is a liver cancer with high expression of IMPDH2. The high expression of IMPDH2 mentioned here may refer to an increased expression of IMPDH2 in cancer tissues, blood, tissue fluid, etc. relative to normal subjects.

[0075] The term "treatment" as used herein includes administration to a human mammal of a cure for a disease, and includes inhibition of a disease. It includes controlling the progression of a disease and alleviating a disease, such as by causing a lost, missing or defective function to return or restore or repair a lost, missing or defective function, or stimulating an inefficient process. Therapeutic therapies can be administered in vivo, in vitro or ex vivo to an organism or cell, including a human, and the cell is then administered to a subject.

[0076] The term "subject" as used herein may include humans and non-human animals. Non-human animals include all vertebrates, such as mammals and non-mammals. A "subject" may also be a livestock animal (e.g., a cow, a pig, a sheep, a chicken, a rabbit, or a horse), or a rodent (e.g., a rat or a mouse), or a primate (e.g., a gorilla or a monkey), or a domesticated animal (e.g., a dog or a cat). A "subject" may be male or female, and may be of different ages. A human "subject" may be an elderly, adult, teenager, child, or infant.

[0077] In some embodiments, the subject described herein is a human or a non-human primate.

[0078] The mTOR inhibitors, STAT3 inhibitors, immune checkpoint inhibitors or pharmaceutical compositions disclosed herein can be administered by routes of administration known in the art, such as injection (e.g., intratumoral injection, subcutaneous injection, intraperitoneal injection, intravenous injection (including intravenous drip or intravenous infusion), intramuscular injection or intradermal injection) or non-injection administration (e.g., oral administration, nasal administration, sublingual administration, rectal administration or topical administration). In some embodiments, the mTOR inhibitors, STAT3 inhibitors, immune checkpoint inhibitors or pharmaceutical compositions described herein are administered by intraperitoneal injection.

[0079] The term "therapeutically effective amount" as used herein refers to the amount of a drug that can alleviate or eliminate a disease or symptom in a subject. A therapeutically effective amount can be the amount of a drug that alleviates one or more diseases or symptoms of a subject to a certain extent; the amount of a drug that can partially or completely restore one or more physiological or biochemical parameters associated with the cause of the disease or symptom to normal; and / or the amount of a drug that can reduce the likelihood of the disease or symptom. In some embodiments, the term "therapeutically effective amount" as used herein refers to the amount of a drug that can alleviate or eliminate a tumor in a subject.

[0080] The therapeutically effective amount of the mTOR inhibitor, STAT3 inhibitor, immune checkpoint inhibitor or pharmaceutical composition provided herein depends on various factors known in the art, such as body weight, age, past medical history, currently receiving treatment, the health status of the subject and the intensity of drug interactions, allergies, hypersensitivity and side effects, as well as the route of administration and the extent of disease development. Those skilled in the art (e.g., doctors or veterinarians) may reduce or increase the dosage accordingly according to these or other conditions or requirements.

[0081] The term "combination therapy" or "combination drug" as used herein refers to the use of a drug in combination with one or more other drugs to treat a disease, including both the combination of a drug with one or more other drugs and the combination of a drug with instructions indicating that the drug can be used in combination with one or more other drugs.

[0082] "Administered simultaneously or sequentially" in the present application refers to the administration of two or more drugs simultaneously or successively at certain time intervals within a dosing cycle (e.g., within 4 weeks, within 3 weeks, within 2 weeks, within 1 week, or within 24 hours), the mode of drug administration (e.g., oral, intravenous, intramuscular or subcutaneous administration, etc.) may be the same or different, and the administration frequency / cycle of two or more drugs may be the same or different. When the method of treatment, product or use disclosed herein involves two drugs, the two drugs may be administered separately at the same time or at certain time intervals. When the method of treatment, product or use disclosed herein involves three drugs, the three drugs may be administered at the same time point, or two drugs may be administered at one time point and the remaining drug may be administered at another time point, or all three drugs may be administered at different time points.

[0083] In some embodiments, the mTOR inhibitors of the present disclosure may be administered before, after, or simultaneously with the STAT3 inhibitors as needed. In some embodiments, the pharmaceutical compositions of the present disclosure may be administered before, after, or simultaneously with the immune checkpoint inhibitors as needed.

[0084] In some embodiments, the treatment further comprises administering an anti-tumor drug to a subject in need thereof. In some embodiments, the mTOR inhibitor, STAT3 inhibitor, immune checkpoint inhibitor and / or pharmaceutical composition is administered before, after or simultaneously with the anti-tumor drug.

[0085] Example

[0086] The experimental methods in the following examples are all conventional methods unless otherwise specified.

[0087] Example 1: Treatment of liver cancer with PD-1 inhibitors leads to low expression of IMPDH2

[0088] Bioinformatics analysis was applied to show the expression of key factors that were significantly reduced in liver cancer patients after anti-PD-1 treatment in public databases. Based on the public data stored in the GEO database, a re-analysis and mining was conducted, and single-cell sequencing data of liver cancer tissues treated with anti-PD-1 (GSE159977 and GSE134921) were selected for integrated analysis, and interactive analysis was performed on key genes that were under-expressed due to PD-1 treatment.

[0089] The results showed that the differential expression profiles of GSE159977 and GSE134921 were integrated and the genes whose expression was suppressed after PD-1 administration were integrated. By taking the intersection, 21 key factors were found, such as IMPDH2, HMGB1, STPG1, DNAJC11, E2F2, ELOA, CDC274, ARAID1A, FBXO42, THAP3, COL9A2, H6PD, VAMP3, TNFRSF9, THRAP3, KIF1B, NDC1, AL138847.2, AC103923.1, SLC35D1 and IL12RB2. Figure 1 The above results suggest that IMPDH2 is closely related to PD-1.

[0090] Example 2: IMPDH2 is highly expressed in tumor cells and is a new target for anti-tumor therapy

[0091] In order to explore the relationship between IMPDH2 and liver cancer, this example uses immunohistochemical staining and immunoblotting to detect the expression of IMPDH2 in tumor tissues.

[0092] Tumor tissues and paired adjacent tissues of 30 patients with liver cancer were collected from Tianjin Cancer Hospital. Immunohistochemistry was used for staining. IMPDH2 antibody (ab131158, Abcam, Cambridge, UK) was used as the primary antibody to detect the expression level of IMPDH2 in liver cancer tumor tissues and adjacent tissues, and statistical analysis was performed. Soybean-sized tissues were then taken, and after extracting tissue proteins through RIPA, 10 μg of protein was taken for immunoblotting. IMPDH2 antibody (ab131158, Abcam, Cambridge, UK) was used as the primary antibody to detect the expression of IMPDH2 in different patient tissues for statistical analysis. The results are shown in Figure 2. Figure 2 shown.

[0093] Immunohistochemistry results showed that IMPDH2 was highly expressed in 93.33% (28 / 30) of liver cancer tumor tissues; immunoblotting results showed that IMPDH2 was highly expressed in 90% (27 / 30) of liver cancer tumor tissues.

[0094] Example 3: Silencing IMPDH2 significantly inhibited liver cancer growth

[0095] In order to confirm the role of IMPDH2 in the proliferation of liver cancer cells, the effect of IMPDH2 on the proliferation and migration of liver cancer cells was explored at the cellular level. The siRNA method was used to reduce the expression level of IMPDH2 in liver cancer cells and detect the effect of its expression on the proliferation and migration of liver cancer cells.

[0096] A clone formation experiment was used to detect the proliferation of liver cancer cells after RNA interference with IMPDH2. The liver cancer cells HepG2 in the logarithmic growth phase were digested with trypsin, resuspended into a cell suspension using complete DMEM medium (basal medium + 10% fetal bovine serum), plated, and transfected with si-IMPDH2 (AAUGAGAAAGUCAUUGUAGGU, SEQ ID NO: 1) and si-NC (AGGUUUACAUGUUCCAAUAUG, control, SEQ ID NO: 4); the cells were seeded in a 6-well culture plate, with 1000 cells / well in each experimental group; the culture was continued until 14 days or the number of cells in most single clones was greater than 50, and the medium was changed every 3 days and the cell status was observed; after the cloning was completed, 4% paraformaldehyde was added to each well for fixation; crystal violet staining and photography were performed. Figure 3 As shown, IMPDH2 has a significant promoting effect on the proliferation and migration ability of liver cancer cells.

[0097] Next, the effect of IMPDH2 on liver cancer cell proliferation was tested in an animal model. Using Crispr cas9 technology, an IMPDH2 knockout liver cancer cell line was constructed. Then, a nude mouse subcutaneous tumor formation experiment was used to detect liver cancer growth after RNA interference with IMPDH2.

[0098] HepG2 hepatoma cells in the logarithmic growth phase were digested with trypsin, resuspended in complete medium (basal medium + 10% fetal bovine serum) into a cell suspension, plated, transfected with si-IMPDH2 (SEQ ID NO: 1) and si-NC (control, SEQ ID NO: 4) three times, digested, counted, and diluted with PBS; 6-week-old BALB / c-nu mice weighing about 20 g (purchased from Beijing Huafukang Biotechnology Co., Ltd.) were selected and injected with 5×10 6 The cells were injected into the armpits of mice to construct a nude mouse subcutaneous tumor model; one week after the injection, the tumor volume and mouse weight were measured once a week, and the mice were killed after 28 days. The tumor tissues of the mice were retained for photographing and cryopreservation.

[0099] The results of the nude mouse subcutaneous tumor formation experiment showed that when IMPDH2 was completely knocked out, it could significantly inhibit the growth of liver cancer cells ( Figure 4 ).

[0100] The above results show that IMPDH2 is a new target for liver cancer treatment and significantly affects the proliferation ability of liver cancer cells.

[0101] Example 4: IMPDH2 / mTOR / STAT3 form a complex

[0102] In order to further explore the function of IMPDH2 in liver cancer, we constructed an IMPDH2 strip mass spectrometer for detection. The specific method is as follows.

[0103] (1) Detection of proteins binding to IMPDH2 using mass spectrometry

[0104] HepG2 liver cancer cells were selected and transfected with IMPDH2 overexpression plasmid (pcDNA3.1-flag-IMPDH2, purchased from PPL Company, Nanjing, Jiangsu Province) and pcDNA3.1-flag-vector plasmid (blank control, purchased from PPL Company, Nanjing, Jiangsu Province), respectively. After 48 hours, proteins were extracted by mild RIPA and incubated with flag-tagged magnetic beads overnight. The gel strips were collected by Western blot experiment and analyzed by mass spectrometry.

[0105] (2) Co-IP and GST-pull down experiments were used to detect the binding of IMPDH2 and mTOR / STAT3

[0106] HepG2 liver cancer cells were selected and transfected with IMPDH2 overexpression plasmid (pcDNA3.1-flag-IMPDH2), mTOR overexpression plasmid (pcDNA3.1-myc-mTOR, purchased from PPL Company, Nanjing, Jiangsu Province) and STAT3 overexpression plasmid (pcDNA3.1-HA-STAT3 plasmid, purchased from PPL Company, Nanjing, Jiangsu Province). After 48 hours, proteins were extracted by mild RIPA and incubated with flag-tagged magnetic beads overnight, and the gel strips were collected by Western blot experiment.

[0107] (3) Use bioinformatics software to predict the protein structure of IMPDH2 binding to mTOR / STAT3.

[0108] The structural data of IMPDH2 (PDB ID: 1b3o), STAT3 (PDB ID: 6TLC) and mTOR (PDB ID: 5H64) were downloaded from the RCSB protein database, and the binding energy and binding site of IMPDH2 and mTOR / STAT3 were analyzed using Discovery Studio software.

[0109] (4) Bioinformatics software was used to predict the physical binding of IMPDH2 protein structure with the mTOR inhibitor everolimus or the STAT3 inhibitor cucurbitacin I.

[0110] By downloading IMPDH2 (PDB ID: 1b3o), mTOR inhibitor everolimus (Drugbank ID: DB01590, molecular structure see Figure 7 A) and STAT3 inhibitor cucurbitacin I (PubChem CID: 5281321, molecular structure see Figure 7 B) Structural data, the binding energy and binding site of IMPDH2 and mTOR / STAT3 inhibitors were analyzed using Discovery Studio software.

[0111] (5) In vitro binding assay was used to detect the binding ability of IMPDH2 and mTOR / STAT3.

[0112] Everolimus or cucurbitacin I was used as the stationary phase and the purified IMPDH2 protein was used as the mobile phase. Everolimus or cucurbitacin I was fixed on the surface of the gold sensor chip and the purified IMPDH2 protein was flowed over the chip surface. The analytical interaction between the sample and the chip surface was analyzed based on the change in the mass change of the metal film surface and the change in the lowest angle of reflected light intensity (SPR angle).

[0113] The results showed that IMPDH2 had a strong interaction with mTOR or STAT3, and this was also verified by Co-IP and GST-pull down in vivo and in vitro experiments ( Figure 5 ). Furthermore, through bioinformatics analysis and calculation, it was found that the binding energy of IMPDH2 and mTOR is -296kcal / mol, which can form a protein-protein complex with lower energy. The residues around the protein-protein interaction interface can form a large number of hydrophobic interactions and hydrogen bonds. These non-covalent bonds can help stabilize the protein-protein complex. The binding energy of IMPDH2 and STAT3 is -237.29kcal / mol, which can form a protein-protein complex with lower energy. The residues around the protein-protein interaction interface can form a large number of hydrophobic interactions and hydrogen bonds. These non-covalent bonds can help stabilize the protein-protein complex ( Figure 6 ).

[0114] The results of in vitro binding SPR detection of the binding ability of IMPDH2 and everolimus showed that IMPDH2 had a strong binding ability with everolimus, and the binding energy was 1.98×10 -7 KD(M). B. The binding energy between IMPDH2 and cucurbitacin I is -8.9 kcal / mol, and there are 8 amino acid binding sites; in vitro binding SPR detection, the binding ability of IMPDH2 and cucurbitacin I, the results show that IMPDH2 has a strong binding ability with everolimus, and the binding energy is 2.195×10 -6 KD(M)( Figure 7 ).

[0115] The above results show that IMPDH2 can directly bind to two key tumor targets, mTOR and STAT3, to exert its function.

[0116] Example 5: Combined use of mTOR and STAT3 inhibitors has a significant synergistic effect against liver cancer

[0117] Based on the above results, the inventors attempted to further explore the relationship between mTOR inhibitors, STAT3 inhibitors and IMPDH2.

[0118] Everolimus is an oral rapamycin derivative that also has improved water solubility and stability and is effective in treating a variety of tumors. First, the binding ability of IMPDH2 and everolimus was calculated using bioinformatics methods. The results showed that the binding energy of IMPDH2 and everolimus was -7.5 kcal / mol, and there were 12 amino acid sites binding, proving that IMPDH2 and everolimus have a good binding effect. The binding ability of IMPDH2 and everolimus was detected using in vitro binding SPR. The results showed that IMPDH2 and everolimus had a strong binding ability, with a binding energy of 1.98×10 -7 KD(M).

[0119] Cucurbitacin I is often used to study the role of STAT3 in tumor development. It can induce apoptosis of various cancer cells and block the cell cycle process. In colon cancer cell lines, cucurbitacin I can reduce cell viability by inhibiting cell migration and invasion and increasing chemical sensitivity. According to the same method as above, the binding energy between IMPDH2 and cucurbitacin I is -8.9kcal / mol, and there are 8 amino acid binding sites, which proves that IMPDH2 has a good binding effect with cucurbitacin I. The binding ability of IMPDH2 and cucurbitacin I was detected by in vitro binding SPR. The results showed that IMPDH2 has a strong binding ability with cucurbitacin I, and the binding energy is 2.195×10 -6 KD(M).

[0120] The above results indicate that IMPDH2 can be targeted by everolimus and cucurbitacin I simultaneously to exert their functions.

[0121] The mTOR inhibitor everolimus and the STAT3 inhibitor cucurbitacin I were used in combination. At the cellular level, clone formation experiment and cell proliferation experiment were used to detect the lowest effective concentrations of everolimus (400 ng / mL) and cucurbitacin I (600 ng / mL). Sorafenib (2 μg / mL), a multi-target drug for liver cancer used clinically, was used as the positive control group. The specific method is as follows.

[0122] HepG2 hepatoma cells in the logarithmic growth phase were digested with trypsin, resuspended in complete medium (basal medium + 10% fetal bovine serum) into a cell suspension, plated, and everolimus (400 ng / mL) and / or cucurbitacin I (600 ng / mL) were added to the medium; cell inoculation: 1000 cells / well were inoculated in each experimental group in a 6-well culture plate; culture was continued until 14 days or the number of cells in most single clones was greater than 50, and the medium was changed every 3 days and the cell status was observed; after cloning was completed, 4% paraformaldehyde was added to each well for fixation; crystal violet staining and photography were performed.

[0123] The results showed that the combination of everolimus and cucurbitacin significantly inhibited the proliferation of liver cancer cells, and compared with the sorafenib group, the inhibition of liver cancer cell proliferation was more significant ( Figure 8 ).

[0124] Furthermore, a nude mouse subcutaneous tumor formation experiment was used to detect the inhibitory effect of everolimus and cucurbitacin on the growth of liver cancer.

[0125] HepG2 cells, a liver cancer cell line, were prepared, digested, counted, and diluted with PBS. Six-week-old BALB / c-nu nude mice weighing about 20 g (purchased from Beijing Huafukang Biotechnology Co., Ltd.) were selected to establish a nude mouse subcutaneous tumor model in the armpit of the mice. 5×10 6 cells, and press with a cotton swab for 1-2 minutes after injection to prevent leakage of cell fluid; when the cells were injected and tumors formed one week later, the mice were randomly divided into a group of 6 and injected with the lowest effective concentrations of everolimus (2.5 mg / kg) and cucurbitacin I (5 mg / kg), respectively. The clinically used multi-target drug for liver cancer, sorafenib, was used as a positive control group and administered once every 3 days for 3 weeks; the tumor volume and mouse weight were measured once a week, and the mice were killed after 28 days, and the tumor tissues of the mice were retained for photographing and cryopreservation.

[0126] Results of nude mouse tumorigenesis experiment ( Fig. 9 ) showed that compared with the positive control drug sorafenib, the combined use of everolimus and cucurbitacin I can significantly inhibit the growth of liver cancer cells, while the anti-tumor effect of the same dose of a single drug is not obvious. The dosage of everolimus used in the combined drug is 2.5 mg / kg, which is significantly lower than the dosage of 10 mg / kg reported in the literature. It can be seen that the present invention reduces the dosage of everolimus and greatly reduces the toxic and side effects of everolimus.

[0127] In summary, the combined use of everolimus and cucurbitacin I has a significant synergistic effect against liver cancer cells compared with single drug.

[0128] Example 6: The combination of everolimus / cucurbitacin I and PD-1 or PD-L1 antibody has a significant anti-liver cancer synergistic effect

[0129] The C57 mouse subcutaneous tumor formation experiment was used to detect the inhibitory effect of everolimus + cucurbitacin I combined with PD-1 or PD-L1 antibodies on liver cancer growth.

[0130] Mouse hepatoma cell line Hep1-6 cells were prepared, digested, counted, and diluted with PBS. Six-week-old C57 mice weighing about 20 g (purchased from Beijing Huafukang Biotechnology Co., Ltd.) were selected to establish a subcutaneous tumor model in the armpit of the mice. 5×10 6 cells, and pressed with a cotton swab for 1-2 minutes after injection to prevent leakage of cell fluid; after the cells were injected and tumors formed one week later, the mice were randomly divided into groups of 6 and injected with the lowest effective concentrations of everolimus (2.5 mg / kg) and cucurbitacin I (5 mg / kg), and / or PD-1 antibody (10 mg / kg, purchased from InVivoMAb anti-mouse PD-1 (CD279)) or PD-L1 antibody (10 mg / kg, purchased from InVivoMAb anti-mouse PD-L1 (B7-H1)).

[0131] The drug was administered for 3 weeks; the tumor volume and mouse body weight were measured once a week. The mice were killed after 28 days, and the tumor tissues of the mice were photographed and frozen.

[0132] The results showed that in the C57 mouse subcutaneous tumor model, the combination of everolimus + cucurbitacin I significantly inhibited tumor growth, and the combination of everolimus + cucurbitacin I and PD-1 / PD-L1 antibody was more effective in inhibiting liver cancer growth than single drug ( Fig.10 ).

[0133] In summary, the combination of everolimus + cucurbitacin I and PD-1 / PD-L1 antibody has a significant synergistic effect against liver cancer compared with single drug.

[0134] Incorporated by Reference

[0135] Each patent and scientific article mentioned herein is incorporated by reference in its entirety for all purposes.

[0136] Equivalence

[0137] The present invention may be embodied in other specific ways without departing from its spirit or essential characteristics. Therefore, the above embodiments should be regarded as illustrative in all cases, rather than limiting the invention described herein. Therefore, the scope of the present invention is indicated by the appended claims rather than by the above description, and it is intended that all changes within the equivalent meaning and scope of the claims are included therein.

Claims

1. Use of cucurbitacin I in the preparation of a synergist for everolimus in the treatment of liver cancer.

2. Use of a pharmaceutical composition in the preparation of a drug for treating liver cancer, the pharmaceutical composition comprising everolimus and cucurbitacin I.

3. The use according to claim 1 or 2, wherein The molar ratio of everolimus to cucurbitacin I is 1:0.1-10, preferably 1:0.2-5, and more preferably 1:0.5-4.

4. The use according to any one of claims 1 to 3, wherein The potentiator or the pharmaceutical composition further comprises an immune checkpoint inhibitor, preferably the immune checkpoint inhibitor comprises a PD-1 antibody and / or a PD-L1 antibody; Preferably, the PD-1 antibody is nivolumab and / or pembrolizumab, and / or the PD-L1 antibody is atezolizumab and / or sintilimab.

5. Use of mTOR inhibitors and STAT3 inhibitors in the preparation of drugs for treating liver cancer.

6. The use according to claim 5, wherein The mTOR inhibitor and / or the STAT3 inhibitor further inhibits the activity of IMPDH2.

7. The use according to claim 5 or 6, wherein The mTOR inhibitor and the STAT3 inhibitor are each independently selected from one or more of small molecule compounds, antibodies, RNAi molecules and antisense nucleic acids.

8. The use according to claim 7, wherein The mTOR inhibitor is selected from everolimus; and / or the STAT3 inhibitor is selected from cucurbitacin I.

9. The use according to claim 7, wherein: The antibody is a monoclonal antibody or a polyclonal antibody; or the antibody is a monospecific antibody or a multispecific antibody; and / or the antibody is a chimeric antibody, a humanized antibody or a fully human antibody.

10. The use according to claim 7, wherein: The RNAi molecule is a small interfering RNA (siRNA), a short hairpin RNA (shRNA) or a micro RNA (miRNA). Preferably, the RNAi molecule has a length of 18-100 bases; preferably, the RNAi molecule is modified to enhance its stability; preferably, the RNAi molecule comprises a nucleotide sequence of any one of SEQ ID NOs: 1-3, or a nucleotide sequence having a sequence identity of 80%, 85%, 90%, 95%, 96%, 97%, 98% or more with any one of SEQ ID NOs: 1-3.

Citation Information

Cited By

  • Application of IMPDH2 inhibitor in prevention or treatment of inflammation

    CN119745896A

  • Pharmaceutical composition and application thereof in preparation of antitumor drugs

    CN119950745A